oasis 1 trial oral semaglutide 50 mg obesity nejm 2023 at a Dose of 25 in Adults with Overweight or oral semaglutide 50 mg obesity
Description
Including more protein in your diet
A 2023 observational study published in Nutrients evaluating semaglutide in women with obesity and PCOS demonstrated significant weight reduction alongside improvements in metabolic parameters, supporting its role in addressing central adiposity
I cant take hormonal treatments for it
Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979)
A clear and complete consent process reduces liability and builds trust
Keeping a log will help you see patterns and changes over time, making it easier to understand how semaglutide is affecting you
